2. Search Result
Search Result
Results for "

recombinant-antibodies

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

27

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99304
    Lumretuzumab

    Anti-Human ERBB3 recombinant Antibody

    		 EGFR Cancer
    Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
    Lumretuzumab
  • HY-P99301
    Lokivetmab

    Anti-Canine IL31 recombinant Antibody

    		 Interleukin Related Inflammation/Immunology
    Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
    Lokivetmab
  • HY-P99953
    Rivabazumab

    		Bacterial Infection
    Rivabazumab is a recombinant antibody against Pseudomonas aeruginosa pcrV .
    Rivabazumab
  • HY-P99478
    Bifarcept

    		IFNAR Inflammation/Immunology
    Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .
    Bifarcept
  • HY-P99324
    Tomuzotuximab

    Anti-Human EGFR recombinant Antibody

    		 EGFR Apoptosis Cancer
    Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
    Tomuzotuximab
  • HY-P99302
    Lulizumab

    Humanized Anti-CD28 recombinant Antibody

    		 CD28 Inflammation/Immunology
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .
    Lulizumab
  • HY-P99271
    Tisotumab

    Anti-Human F3 recombinant Antibody

    		 ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
    Tisotumab
  • HY-P99332
    Visilizumab

    Anti-Human CD3E recombinant Antibody; HuM291

    		 Apoptosis Inflammation/Immunology
    Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
    Visilizumab
  • HY-P99328
    Tucotuzumab

    Anti-EPCAM recombinant Antibody; huKS-IL2

    		 Interleukin Related Inflammation/Immunology Cancer
    Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
    Tucotuzumab
  • HY-P99274
    Xentuzumab
    1 Publications Verification

    BI 836845; Anti-Human IGF1 and IGF2 recombinant Antibody

    		 IGF-1R Cancer
    Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
    Xentuzumab
  • HY-P99313
    Quilizumab

    Anti-Human NGcGM3 recombinant Antibody

    		 Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research .
    Quilizumab
  • HY-P99264
    Inotuzumab

    Humanized Anti-CD22 recombinant Antibody

    		 ADC Antibody CD22 Cancer
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
    Inotuzumab
  • HY-P99335
    Vunakizumab

    Anti-Human IL17A recombinant Antibody

    		 Interleukin Related Inflammation/Immunology
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
    Vunakizumab
  • HY-P99263
    Inclacumab

    Anti-Human selectin P recombinant Antibody

    		 P-selectin Cardiovascular Disease
    Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
    Inclacumab
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 recombinant Antibody

    		 EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-P99280
    Bimekizumab

    Anti-Human IL17A/IL-17F recombinant Antibody

    		 Interleukin Related Inflammation/Immunology
    Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
    Bimekizumab
  • HY-P99252
    Itolizumab

    Anti-Human CD6 recombinant Antibody

    		 CD6 Infection Inflammation/Immunology
    Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
    Itolizumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: